Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Mnmd | Vintage Vibes

Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026

As mental health treatment evolves, MindMed’s advancing psychedelic pipeline and strong 2025 rally have Jones Trading penciling in gains that could more than quadruple the stock from here.

Barchart

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.

Benzinga

The Insider Report: Panic Never Pays

It was a pretty quiet week until Friday. Trade tensions with China are soaring again, and it sent stocks tumbling into the close. Could we really see 100% tariffs on China? I think it's an exaggeration, and the best dip buying opportunity in months. Be ready. The Dow Jones Industrial…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

With Phase 3 results for its lead psychedelic therapy expected next year, is now the right time to take a bold bet on MNMD stock?

Barchart

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Barchart

1 Small-Cap Biotech That Analysts Expect to Triple

As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.

Barchart

Buy the Dip in This Biotech After Negative FDA News, Says Analyst

MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Growth Stocks Under $10 With Breakout Potential

Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.

Barchart

Up 163% YTD, Is It Too Late to Buy MindMed Stock?

Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?

Barchart

3 Stocks Under $10 Analysts Expect to Double

Here's a closer look at three low-priced stocks - MNMD, ASPN, and BEEM - that Wall Street is expecting to double (or more) from current levels.

Barchart

MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.

Benzinga

MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes

MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offer

Benzinga

MindMed Reports Financial Results For Q1, With Lower Cash Balance Compared To December Last Year

MindMed (NASDAQ: MNMD) announced its financial results for the first quarter of 2022, which ended March 31.

Benzinga

Earnings Preview For Mind Medicine

Mind Medicine (NASDAQ:MNMD) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Mind Medicine will report an earnings per share (EPS) of $-0.05.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Benzinga

From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers

With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ:MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and member of…

Benzinga

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

Benzinga

MindMed Reports Full Year 2021 Financial Results, Announces Changes In Leadership

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Cash balance as of December 31, 2021, was $133.5 million compared to $80.1 million as of December 31, 2020. Net cash in operating activities was $45.8 million for…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

LSD And Magic Mushroom's Active Compound Appear To Have The Same Effects, New Study Finds

A new peer-reviewed study compared the effects of LSD and psilocybin, two substances currently standing as top molecules behind the recent psychedelic medicine boom. While both compounds have a rich history of human use, not much research has been dedicated to contrasting the effects they produce in human psychology. The…

Benzinga

MindMed Converts Shares To Have A Single Class

Psychedelics-focused biopharma company Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), (DE:MMQ) confirmed Wednesday that all the company’s issued and outstanding multiple voting shares will undergo a mandatory conversion into subordinate voting shares in accordance with the company&rsq

Benzinga

Psychedelic Stock Gainers And Losers From February 15, 2022

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 10.74% at $1.34

Benzinga

MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years

MindMed (NASDAQ: MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog.

Benzinga

Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 25.48% at $1.17

Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jan. 25, 2022: MSFT, SHOP, ERIC, MNMD, TSLA

Today's 5 Stock Ideas: Microsoft (MSFT) - The company reports Q2 earnings today after the close. Shopify (SHOP) - Shares down premarket. Keybanc lowered its price target on the stock from $1750 to

Benzinga

MindMed Launches Study Using Monitoring System For Psychedelic Experiences

Psychedelics biotech company MindMed (NASDAQ: MNMD) has enrolled the first subjects into its Session Monitoring System study. The company’s Session Monitoring System is a technology platform that can collect sensory data during a therapy session with a psychedelic drug.

People

Spencer Cox

248 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Ohio State University

118 stories

ERIC

89 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.